The invention relates to leukotriene B4 derivatives of general formula (I) in which R1 stands for H, CF3, CH2OH; R2 stands for an organic acid radical; R3 stands for H, C1-C14-alkyl, C3-C10-cycloalkyl, or a 5-6-link aromatic heterocyclic ring with at least one heteroatom; R4 is hydrogen, C1-C10-alkyl, C3-C10-cycloalkyl; A is a trans-, trans-CH=CH-CH=CH, a -CH2CH2-CH=CH- or a tetramethylene group; B is a C1-C10 linear or branched-chain aklylene group or the group (a) or (b); D is a direct bonding, oxygen, sulphur, -C C-, -CH=CR7, or a direct bonding with B; R5 and R6 are identical or different and are H or C1-C4-alkyl, or R6 stands for H and R5 stands for C1-C15-alkanoyl or R8 SO2-; R7 is H, C1-C5-alkyl, chlorine, bromine; R8 is the same as R3; m is 1-3; o is 0-5; p is 0-5; x is a direct bonding, oxygen, sulphur, an aromatic or heterocyclic compound; y is a C1-C8-alkyl, C3-C10-cycloalkyl; n is 2-5. When R4 is hydrogen, the invention also relates to their salts with physiologically compatible bases and their cyclodextrin clathrates. The leukotriene derivatives are used as dermatological products.